Mendus AB (publ) (IMMU) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to MENDES Q2 Report 2025 presentation. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Eric Manting and CFO Lotta Firm. Please go ahead. Thank you and welcome everybody to the Q2 webcast and business update of MENDES. As a summary of the key events in Q2, we have presented data at multiple conferences of the ongoing Advanced 2 Phase 2 trial in acute myeloid leukemia, showing that our immunotherapy VD-Den cell improves T-cell repertoire and also that it acts across broader mutation ranges of AML. We had shown this in the past already in our earlier studies, but now also in the ADVANCE-II trial, we specifically focused on a common mutation called NPM-1. The relevance of this is that we are showing and continue to show that we stimulate broad immunity against residual disease and also that our product acts across different subtypes of AML. And that makes it very different from targeted therapies that by definition are always dependent on specific mutations being present in the disease, and also with quite a high risk of what's called clonal escape. So if you put a lot of pressure on one specific mutation, patients will develop new clones of the disease that will be resistant to that specific drug targeting that mutation. And the fact that we see a very broad immune stimulation, and also in this set of data, but also earlier data sets, that there was no association between the effectiveness of the product and the actual cytogenetics or the makeup of the tumor that makes it a very suitable strategy broadly across AML subtypes. Then we are progressing with NorthX Biologics and our manufacturing alliance to deliver large-scale G...